C4 Therapeutics (NASDAQ:CCCC) Stock, Quote.Headers.trade-ideas

C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

BITF

CCCC

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

NNOX

SSRM

TVGN

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 50 points on Tuesday.

Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days.

What&#39;s Going On With C4 Therapeutics Stock?

Stock_Whisper_Index_Logo_6-copy

Exclusives

AMZN

FRGT

INHD

STTK

TPIC

A look at five stocks that saw increased interest from Benzinga readers during the week.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

C4 Therapeutics Inc

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

The latest announcement is out from C4 Therapeutics (CCCC). C4 Therapeutics, Inc. has partnered with Merck KGaA in a significant deal to advance ca...

C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA

C4 Therapeutics (CCCC) has shared an update. C4 Therapeutics, Inc. has initiated a strategic repricing of stock options to incentivize and retain k...

C4 Therapeutics Initiates Stock Option Repricing for Retention

C4 Therapeutics Inc (CCCC) is around the top of the Biotechnology industry according to InvestorsObserver. CCCC received an overall rating of 76, which means that it scores higher than 76 percent of all stocks. C4 Therapeutics Inc also achieved a score of 91 in the Biotechnology industry, putting it above 91 percent of Bio

C4 Therapeutics Inc (CCCC) has fallen -18.87% in a Week, Should You Hold?

C4 Therapeutics GAAP EPS of -$0.41 in-line, revenue of $3.04M misses by $6.24M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>C4 Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cccc-stock-quote/"><strong>CCCC</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>C4 Therapeutics reported earnings per share of -41 cents. This was below the analyst estimate for EPS of -35 cents.</li><li>The company reported revenue of $3.04 million.</li><li>This was 62.48% worse than the analyst estimate for revenue of $8.10 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/cccc-stock-earnings-c4-therapeutics-for-q1-of-2024/">CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024

In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on C4 Therapeutics (CCCC – Research Report), with a price t...

C4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable Financials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC – Research Report), ACADIA Pharmaceuticals ...

Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)

C4 Therapeutics (CCCC) has provided an update. The Company has announced Mr. Cooper's addition to its Board with a press release, emphasizing that ...

C4 Therapeutics Appoints Mr. Cooper to Board

C4 Therapeutics: Losing Steam And Presenting An Opportunity

ACAD

IRON

Health Care

Press Releases

General

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Earnings

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Opinion

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

Management

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

C4 Therapeutics

C4 Therapeutics (CCCC) Forecast

C4 Therapeutics (NASDAQ:CCCC) Stock, Quote.Headers.trade-ideas